Xcytrin (motexafin gadolinum) / AbbVie  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xcytrin (motexafin gadolinum) / AbbVie
NCT00003736: MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

Completed
N/A
200
Canada, US
motexafin gadolinium, biopsy, breast imaging study, comparison of screening methods, magnetic resonance imaging, study of high risk factors
Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI)
Breast Cancer
06/02
06/02
NCT01562223: Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer

Active, not recruiting
N/A
30
US
motexafin gadolinium, Gadolinium
American College of Radiology Imaging Network, National Cancer Institute (NCI)
Prostate Cancer
12/22
12/22
NCT04809584: 18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Approved for marketing
N/A
US
F18-DCFPyL, Gadolinium, motexafin gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
Stanford University
Prostate Cancer
 
 
ACRIN6690, NCT01082224: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

Active, not recruiting
N/A
440
US
iodinated contrast dye, iodinated radiographic dye, motexafin gadolinium, Xcytrin, Eovist-enhanced MRI
American College of Radiology Imaging Network, National Cancer Institute (NCI)
Liver Cancer
12/23
12/23

Download Options